On Air Now

Upcoming Shows

Program Schedule »


Listen Live Now » 1360 AM Northeast, WI 97.5 FM Green Bay, WI


Current Conditions(Green Bay,WI 54303)

More Weather »
72° Feels Like: 72°
Wind: SSW 14 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Partly Cloudy 70°


Scattered Thunderstorms 62°


PM Thunderstorms 76°


Biodel's insulin drug found effective in mid-stage trial

(Reuters) - Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial.

Shares of the specialty pharmaceutical company rose 10.5 percent before the bell.

The study was testing the drug, BIOD-531, against Eli Lilly and Co's Humalog Mix 75/25 in type 2 diabetes patients with moderate insulin resistance who use 50-200 units of insulin daily.

In type 2 diabetes, the most common form of the disease, the body does not use insulin properly, leading to high levels of blood sugar.

Basal insulin, or long-acting insulin therapies, are usually prescribed to keep blood sugar levels in control between meals. Prandial insulin, or short-acting insulin therapies, are administered before meals to manage mealtime glucose.

Type 2 diabetes patients are usually given both basal and prandial insulin in a single injection such as Humalog Mix 75/25, Biodel said.

Humulin R U-500 is the only concentrated insulin available in the United States, the company said.

The therapy is used to treat type 2 diabetes patients with severe insulin resistance, who need greater than 200 units of insulin daily.

Danbury, Connecticut-based Biodel's shares closed at $1.91 on the Nasdaq on Friday.

(Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey)